

Circassia Pharmaceuticals

Joining the dots

Circassia's recent interims demonstrated 55% y-o-y revenue growth to £28.4m and a 75% R&D expense reduction (to £6.9m from £27.2m in H117) while growing the commercial infrastructure that now includes China. Investors should see a path to profitability, but we note recent licensing opportunities in the respiratory therapeutic area could accelerate this.

Circassia's transformation

Circassia has moved past R&D disappointments and transformed into a respiratory specialty pharmaceutical company with the potential for profitability. Circassia's revenues (from its respiratory products Tudorza for COPD and NIOX) grew to £28.4m in H118 from £18.3m in H117. Just as important was the cost discipline, as illustrated by a 26% y-o-y fall in operational costs, helped by a 75% reduction in R&D spend. Circassia ended H118 with £50.8m in cash (£59.5m at YE17).

Big opportunities in respiratory space

Changing priorities at the UK's biggest pharma companies could bring opportunities in the respiratory space. GlaxoSmithKline's (GSK's) recent Q318 results included a pruning of its once-dominant respiratory pipeline of three experimental products; media reports (by GSK's head of oncology) have suggested a side-lining of the franchise with resources diverted to other therapeutic areas. In addition, after nine quarters of product sales declines, AstraZeneca is divesting its formerly most treasured but deprioritised respiratory brands such as Alvesco for asthma.

Therapeutic specialty and in-licensing record

Circassia in-licensing deprioritised complementary respiratory products from big pharma would make commercial sense, and is a logical fit beyond Circassia's COPD product focus. Circassia's commercial infrastructure will be leveraged once the second product from the AstraZeneca transaction, Duaklir, is approved, but a more complete respiratory portfolio, containing an inhaled corticosteroid (alone or in combination), could expand the franchise to asthma and further utilise the salesforce. In addition, the AstraZeneca deal has given Circassia a track record of structuring transactions that involve deferred and option payments, loans and share purchases without significant shareholder dilution.

Valuation: Few specialty respiratory peers

There are few opportunities for commercial respiratory exposure and, with an EV of c £151m, past R&D issues may still be discounting Circassia's valuation.

Consensus estimates						
Year end	Revenue (£m)	PBT (£m)	EPS (p)	DPS (p)	P/E (x)	Yield (%)
12/16	23.1	(64.9)	(20.0)	N/A	N/A	N/A
12/17	46.3	(40.4)	(11.0)	N/A	N/A	N/A
12/18e	56.4	(27.2)	(6.9)	N/A	N/A	N/A
12/19e	76.3	(26.9)	(6.7)	N/A	N/A	N/A

Source: Reuters


Pharma & biotech

8 November 2018

Price 58.85p Market cap £210m

GBP:US\$1.3

Share price graph



Share details

Code CIR
Listing LSE
Shares in issue 357.2m

Business description

Circassia Pharmaceuticals operates as a specialty pharmaceutical company focusing on respiratory disease. It offers an asthma management diagnostic product (NIOX) and, in collaboration with AstraZeneca, the COPD therapies Tudorza, which is on the US market, and Duaklir, which is under review by the FDA.

Bull

- A viable commercial respiratory franchise.
- A rare path to near-term profitability among UK biotechs.
- AstraZeneca collaboration and cash of c £51m.

Bear

- Past R&D failures still cloud the stock.
- Time to profitability dependent on organic growth.
- Incomplete respiratory portfolio.

Analyst

Andy Smith +44 (0)20 3077 5700

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



dison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholes ale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is sixed in Australia by Edison Investment Research Ply Ltd (Corporate Authorised Representative (152501) of Myonlineadvisers Ply Ltd (AFSL: 42744)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers" exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information or that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(i) (11)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or